Prenatal Treatment for Spinal Muscular Atrophy Showcases New Horizons in Genetic MedicineIn a historic medical breakthrough, a child born with spinal muscular atrophy (SMA), a severe motor neuron disease, exhibits no symptoms after receiving prenatal treatment with the gene-targeting drug Risdiplam. This pioneering intervention, documented in the New England Journal of Medicine, marks the first instance of treating SMA before birth.
on
February 24, 2025
Cracking CXCR2: A Breakthrough for Cancer and Respiratory CareResearchers at the Indian Institute of Technology (IIT) Kanpur have achieved a major milestone by visualizing the atomic structure of CXCR2, a key receptor implicated in cancer progression and severe respiratory disorders such as COPD and asthma. Their cutting-edge findings, published in Molecular Cell, could open new therapeutic avenues for clinicians worldwide.
on
February 22, 2025
ZEISS Inaugurates AI Lab at IISc to Transform Eye CareZEISS India has inaugurated a state-of-the-art AI research facility at the Indian Institute of Science (IISc), Bangalore, targeting breakthrough solutions in ophthalmology. Supported by the Spectrum Lab in the Department of Electrical Engineering, this collaboration is poised to offer doctors cutting-edge tools for early detection and improved patient outcomes.
on
February 21, 2025
Sanofi’s Merilog: A New Era in Rapid-Acting Insulin BiosimilarsThe FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to NovoLog, marking a significant milestone as the first rapid-acting insulin biosimilar. Designed for both adult and pediatric patients with diabetes mellitus, Merilog offers clinicians an additional option for effective glycemic control.
on
February 20, 2025
India to Launch Breakthrough Cancer Vaccine for WomenIn a significant move to combat rising cancer cases in India, Union Minister of State for Health, Family Welfare, and Ayush (Independent Charge) Prataprao Jadhav has announced a groundbreaking vaccine targeting cancers that predominantly affect women. The vaccine, currently in its final research phase, is expected to be available within five to six months. It will be administered to girls aged 9 to 16, focusing on preventing breast, oral, and cervical cancers.
on
February 19, 2025

Featured

FDA Approves Blujepa (Gepotidacin): First New Oral Antibiotic for uUTIs in Nearly 30 Years
Lorundrostat Shows Promise in Treating Uncontrolled Hypertension in Pivotal Trials
Kerala School Reports Viral Meningitis Cases, Health Authorities on High Alert
DCGI’s Renewed Mandate: Wiping Out Substandard Drugs, Supporting MSMEs, and Regulating Medical Devices
Delhi Sees Surge in H1N1 and Influenza B Cases

Participate in India’s healthcare revolution

Create ABHA & store all your medical records with Eka care (Govt of India ABDM approved PHR app)

Create ABHA ID

Popular topics

#

newfeature

#

Partnership

#

funding